siteman investment program karen kharasch, executive director
TRANSCRIPT
SITEMAN CANCER CENTER
Disclosure Information
I have no financial relationships to disclose.
2015 CCAF Annual Meeting
PI Members
Grants awarded
Programs NCI & NIH
Other Peer Review
Non Peer Reviewed
SITEMAN CANCER CENTER
4
83107
7
$ 39.2 million 71 Leveraged grants
$12.4 millionSIP awarded grants
45%32
4%
51%
3
36
Siteman Investment Program (SIP)2009 – 2014
PROFILE
SITEMAN CANCER CENTER
Evaluation of RFAs and Review Process
• 5 annual scientific review committees
• Extreme difficulty finding reviewers
• Faculty feedback:– Uncertain what the reviewers/Senior Leadership wants– Transparency– Consistency of announcement
• Competitive renewals for all 2 year awards
Difficulties
5
SITEMAN CANCER CENTER
New SIP Model
The following current Siteman RFAs will now be incorporated into the new review model
– SCC Research Development Awards (RDA) – Breast Cancer Program Career Development (CDA) – Breast Research Development Awards– Cancer Frontier Fund (CFF) – ACS-IRG will be a sub-study section
Streamline & Transparent
SITEMAN CANCER CENTER
Assumptions
Total awards are dependent on philanthropy – The number of awards and the award amount may increase
or decrease each year dependent on SCC philanthropy
Total awards are dependent on scientific merit – The number of awards and the award amount may increase
or decrease each year dependent on scientific merit of the applicants at each study section
SITEMAN CANCER CENTER
• Discovery, diagnosis, treatment and public health •New diagnostic tests, imaging technology, drug, vaccine,
or other cancer therapy • Accelerate discoveries to test and verify pioneering
options• Produce data that provide the basis for future applications
(such as R01s, R21s, DOD, SPOREs, PPGs, etc.) or the opportunity for business creation and venture funding• Catalyze discoveries by building bridges among disciplines
and researchers in St. Louis (WU, WUSM, SLU and soon UMSL)
Create an agile study section model in order to provide pilot funding for SCC members in discovery, diagnosis, treatment and public health
SITEMAN CANCER CENTER
Total awardfor 2 years
(direct costs)
# of awards Cycle 1 Cycle 2
Announced January 1 July 1
Due date May 1 October 1
Start date July 1 January 1
Pre-R01 $400,000 2 2
Pre-SPORE/PPG $ 800,000 1 1
Multi-PI Pre-R01 $400,000 1 1
Danforth/Consortium Pre-R01 $ 200,000 1 1
Total awarded for 2 years $ 1,800,000 5 5
SITEMAN CANCER CENTER
SIP Study Section Structure
•21 - 28 reviewers– Recommended and assigned by each program leaders– Rotating Chairs by program– Internal competition reviews as required–Ad hoc leadership: Associate Directors of Basic Science, Translation, Shared Resources and Executive Director
Representatives from all Programs
SITEMAN CANCER CENTER
SIP Study Section Structure
– Each review cycle will have 14 of the 21 reviewers – Ad hoc reviewers as required– Reviewers will serve 3 year term– Required to participate in 4 of the 6 reviews in the three year period– Rotate off after 4 study sections – Allows reviewers to take off a cycle to submit
Rotation of Reviewers
SITEMAN CANCER CENTER
Funds Allotment Review
– Chairs of the Study Section– Associate Directors of Basic, Translation Science and
Shared Resources – Executive Director– VP BJH Foundation– BJH Foundation Board member– Pedal the Cause Executive Director– Business Director
Funding Review
SITEMAN CANCER CENTER
Budget and Scientific Review
Budget–Business Director & staff have access to all Siteman
SIP accounts
Science–Scientific progress is reported once a year.